Investigating the role of the complement pathway in lung diseases
Official title: Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung Diseases
Funded at Duke University · NIH-11011341 · Data updated 2026-11-12
This study is looking at how certain proteins in your body might help us understand the progression of idiopathic pulmonary fibrosis and similar lung diseases, so we can find better treatments tailored just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $189,252 |
| NIH project number | 5K23HL163381-03 |
| Project ID | NIH-11011341 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
✕Less likely to help
Patients with non-progressive lung diseases or those not diagnosed with PF-ILD may not receive any benefit from this research.
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILDs), which lead to severe lung function decline. The study aims to understand how the complement pathway, a part of the immune system, may serve as a biomarker for disease progression and acute respiratory events. By analyzing specific proteins and genetic variations in patients, the research seeks to identify those who may benefit from targeted therapies. The ultimate goal is to develop novel treatments that improve patient outcomes and personalize care based on biomarker findings.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options and improved management strategies for patients with PF-ILD.
How similar studies have gone: Previous research has shown promise in using biomarkers for disease progression in similar lung conditions, indicating potential for success in this approach.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Swaminathan, Aparna Chandra — Duke University
- Study coordinator: Swaminathan, Aparna Chandra
Related research
Other NIH-funded projects on the same topics.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information.
This study is looking to help people with Idiopathic Pulmonary Fibrosis (IPF) by using their genetic information to find the best treatments for them, so they can get care that’s more personalized and effective.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information
This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.